Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by SciSparc Ltd
< Previous
1
2
3
Next >
SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles
January 13, 2025
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results
January 07, 2025
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
January 06, 2025
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
SPRC
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder
December 31, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation
December 26, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company
December 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
TSX-V:MIZA-P
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
September 30, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
September 26, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
September 23, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
September 18, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
September 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer
September 11, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
September 06, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
SPRC
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
August 29, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
August 28, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
August 23, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
August 22, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
August 19, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
August 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Updates Regarding the Status of the AutoMax Merger
August 14, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
August 06, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
SPRC
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
July 22, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
July 17, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
July 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
July 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
SPRC
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
July 08, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
TSX-V:MIZA-P.V
SciSparc Secures Strategic Advantage with Grant of European Patent
May 31, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc to Acquire AutoMax
April 11, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
March 27, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
March 21, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.